New biomarkers identified for pancreatic cancer and mesothelioma

Harris, Jason; Southall, Jennifer
October 2010
Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p22
The article discusses research being done on the biomarkers and protein signatures for detecting pancreatic cancer and mesothelioma, which references a study by presented at the American Association for Cancer Research (AACR) International Conference in Denver, Colorado from September 27-30, 2010.


Related Articles

  • news@JAMA.  // JAMA: Journal of the American Medical Association;6/27/2012, Vol. 307 Issue 24, p2577 

    The article offers medical news briefs as of June 2012 on topics including effect of 2008 Summer Olympics of Beijing on the biomarkers, pancreatic cancer prediction and increase in sleepwalk in the U.S.

  • Increased erythropoietin levels as a biomarker of pancreatic adenocarcinoma: A case report. KHAN, RAFAY; QIANG NAI; PING ZHANG; HONGXIU LUO; SEN, SHRAMAN; SIDHOM, IBRAHIM; MATHEW, TEENA; ISLAM, MOHAMMAD; SEN, SHUVENDU; YOUSIF, ABDALLA // Molecular & Clinical Oncology;Jan2016, Vol. 4 Issue 1, p134 

    Pancreatic cancer is one of the deadliest cancers commonly diagnosed at an advanced stage. Early diagnosis is crucial for the timely and potentially curative treatment of this highly fatal disease. Although screening tests have improved the survival rate in malignancies such as colon, breast,...

  • MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. Dillhoff, Mary; Liu, James; Frankel, Wendy; Croce, Carlo; Bloomston, Mark // Journal of Gastrointestinal Surgery;Dec2008, Vol. 12 Issue 12, p2171 

    Background: MicroRNAs are small (18-22 nucleotides) noncoding RNAs involved in posttranscriptional modification of many target genes. One of these, microRNA-21 (miR-21), has been shown to play a role in multiple hematologic and solid organ malignancies. We sought to determine the...

  • PGE2 in Pancreatic Cyst Fluid Helps Differentiate IPMN from MCN and Predict IPMN Dysplasia. Schmidt, C. Max; Yip-Schneider, Michele T.; Ralstin, Matthew C.; Wentz, Sabrina; DeWitt, John; Sherman, Stuart; Howard, Thomas J.; McHenry, Lee; Dutkevitch, Sarah; Goggins, Michael; Nakeeb, Attila; Lillemoe, Keith D. // Journal of Gastrointestinal Surgery;Feb2008, Vol. 12 Issue 2, p243 

    Current management of intraductal papillary mucinous neoplasm (IPMN) according to recently published International Consensus Guidelines depends upon distinguishing it from mucinous cystic neoplasms (MCNs). We have previously shown that prostaglandin E2 (PGE2) is increased in pancreatic cancer...

  • High Expression of Plasminogen Activator Inhibitor-2 (PAI-2) is a Predictor of Improved Survival in Patients with Pancreatic Adenocarcinoma. Schindl, M. J. // World Journal of Surgery;Mar2007, Vol. 31 Issue 3, p503 

    The article focuses on the characterization of molecular markers for pancreatic cancer prognosis. High expression of urokinase plasminogen activator and receptor, and plasminogen activator inhibitor type 1 are connected with a poor prognosis. These plasminogen activators serve as a predictive...

  • Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer. Kojima, Kyoko; Asmellash, Senait; Klug, Christopher A.; Grizzle, William E.; Mobley, James A.; Christein, John D. // Journal of Gastrointestinal Surgery;Oct2008, Vol. 12 Issue 10, p1683 

    Background: The proteome varies with physiologic and disease states. Few studies have been reported that differentiate the proteome of those with pancreatic cancer.Aim: To apply proteomic-based technologies to body fluids. To differentiate pancreatic neoplasia from...

  • Development of candidate biomarkers for pancreatic ductal adenocarcinoma using multiple reaction monitoring. Yu, Jiyoung; Kim, Kyunggon; Kang, MeeJoo; Kim, Hyunsoo; Kim, Sun; Jang, Jin-Young; Kim, Youngsoo // Biotechnology & Bioprocess Engineering;Sep2013, Vol. 18 Issue 5, p1038 

    Pancreatic ductal adenocarcinoma (PDAC) is the fourth most frequent cause of cancer mortality in the United States. Because CA 19-9 increases not only in PDAC, but also in benign conditions, there is urgent need for an additional PDAC biomarker. Isotope tags for relative and absolute...

  • Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening. Pérez-Torras, Sandra; Vidal-Pla, Anna; Miquel, Rosa; Almendro, Vanessa; Fernández-Cruz, Laureano; Navarro, Salvador; Maurel, Joan; Carbó, Neus; Gascón, Pere; Mazo, Adela // Cellular Oncology (2211-3428);Dec2011, Vol. 34 Issue 6, p511 

    Background: Efforts to identify novel therapeutic options for human pancreatic ductal adenocarcinoma (PDAC) have failed to result in a clear improvement in patient survival to date. Pancreatic cancer requires efficient therapies that must be designed and assayed in preclinical models with...

  • Protection against azaserine induced pancreatic cancer in rats by Phyllanthus amarus: a preliminary study. Revathia, R.; Murugesana, M.; Manju, V. // Journal of Biochemical Technology;2011, Vol. 3 Issue 3, p1 

    Pancreatic cancer is a major cause of morbidity and mortality in developed and developing countries. We studied the chemopreventive effect of Phyllanthus amarus on tissue lipid peroxidation and antioxidant status, which is used as biomarkers in azaserine induced pancreatic carcinogenesis in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics